Civilization Ventures (inquiries to info@civilizationventures.com) invests in visionary founders that are leading the future of health tech and biology-driven innovation. They aim to be the first check and lead investor in highly disruptive companies in synthetic biology and exponential health tech (genomics, diagnostics, digital health, AI, personalized and regenerative medicine). Their team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of their portfolio companies succeed. They celebrated their first "unicorn" exit in 2018 with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and their second exit with the acquisition of Singular Bio (non-invasive prenatal testing) by Invitae.

Venture Capital

Civilization Ventures

Org chart

Teams

Leadership Team

Similar companies